Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Spezifität
RASSF10 antibody will not cross-react with other RAS association domain-containing family members.
Aufreinigung
RASSF10 Antibody is affinity chromatography purified via peptide column.
Immunogen
RASSF10 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human RASSF10. The immunogen is located within amino acids 50 - 100 of RASSF10.
RASSF10 antibody can be used for detection of RASSF10 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
RASSF10 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
RASSF10 antibody can be stored at 4 °C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
RASSF10
(Ras Association (RalGDS/AF-6) Domain Family (N-Terminal) Member 10 (RASSF10))
4632411J06Rik antikoerper, Ras association domain family member 10 antikoerper, Ras association (RalGDS/AF-6) domain family (N-terminal) member 10 antikoerper, RASSF10 antikoerper, Rassf10 antikoerper
Hintergrund
RASSF10 Antibody: RASSF10 is a member of the N-terminal Ras association domain-containing family of proteins, a family of tumor suppressor genes that are frequently epigenetically inactivated in cancer. These proteins consist of RASSF7-10 and are structurally distinct from RASSF1-6, containing the N-terminal Ras association domain but lacking the Sav/RASSF/Hippo protein interaction domains. While little is known of the function of RASSF10, it is inactivated in both childhood leukemia and gliomas. In secondary glioblastomas, RASSF10 methylation can be used as an independent prognostic associated with worst progression-free survival and overall survival.